Target species
Pigs (sows and gilts).
Indications for use
For the passive immunisation of piglets by active immunisation of sows/gilts to reduce mortality and clinical signs such as diarrhoea due to neonatal enterotoxicosis during the first days of life, caused by those E.coli strains, which express the fimbrial adhesins F4ab (K88ab), F4ac (K88ac), F5 (K99) or F6 (987P).
Contraindications
None.
Special warnings for each target species
Vaccinate healthy animals only.
Special precautions for use
Not applicable.
Operator warnings
In the case of accidental self-injection, seek medical advice immediately and show the package leaflet or label to the physician.
Adverse reactions
Pigs (sows and gilts):
Very common (>1 animal / 10 animals treated): | Elevated temperature1, Listless2, Reduced food intake2 Injection site reaction3 |
1 Up to 3 °C, for up to 1 day after vaccination.
2 For up to 3 days after vaccination.
3 Recedes within 14 days, may occasionally exceed a diameter of 5 cm.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy or lactation
Can be used during pregnancy.
Interactions
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. It is therefore recommended that no other vaccine should be administered within 14 days before or after vaccination with this product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.
Amounts to be administered and administration route
Intramuscular use.
Administer one dose (2 ml) per animal by intramuscular injection in the neck in the area behind the ear of sows/gilts.
Vaccination scheme:
Basic vaccination: Sows/gilts which have not yet been vaccinated with the product shall be given an injection preferably 6 to 8 weeks before the expected date of farrowing followed by a second injection 4 weeks later.
Revaccination: A single revaccination shall be carried out during the second half of each subsequent pregnancy, preferably 2 to 4 weeks before the expected date of farrowing.
Overdose
No undesirable effects other than those observed and mentioned in the “Adverse reactions” section have been observed.
Withdrawal period
Zero days.